Literature DB >> 16175621

Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD Era.

Cristina Ripoll1, Rafael Bañares, Diego Rincón, María-Vega Catalina, Oreste Lo Iacono, Magdalena Salcedo, Gerardo Clemente, Oscar Núñez, Ana Matilla, Luis-Miguel Molinero.   

Abstract

Measurements of portal pressure, usually obtained via the hepatic venous pressure gradient (HVPG) may be a prognostic marker in cirrhosis. The aim of this study was to evaluate the impact of HVPG on survival in patients with cirrhosis in addition to the Model for End-Stage Liver Disease (MELD) score. We also examined whether inclusion of HVPG in a model with MELD variables improves its prognostic ability. Retrospective analyses of all patients who had HVPG measurements between January 1998 and December 2002 were considered. Proportional hazards Cox models were developed. Prognostic calibrative and discriminative ability of the model was evaluated. In this period, 693 patients had a hepatic hemodynamic study, and 393 patients were included. Survival was significantly worse in those patients with greater HVPG value (univariate HR, 1.05; 95% CI, 1.02-1.08; P = .001). HVPG remained as an independent variable in a model adjusted by MELD, ascites, encephalopathy, and age (multivariate HR, 1.03; 95% CI, 1.00-1.06; P = .05) so that each 1-mmHg increase in HVPG had a 3% increase in death risk. In addition, HVPG as well as MELD score variables and age, significantly contributes to the calibrative predictive capacity of the prognostic model; however, discriminative ability improved only slightly (overall C statistic [95% CI]; MELD score variables: 0.71 [0.62-0.80], MELD score variables, age, and HVPG 0.76: [0.69-0.83]). In conclusion, HVPG has an independent effect on survival in addition to the MELD score. Although inclusion of HVPG and age in a survival predicting model would improve the calibrative ability of MELD, its discriminative ability is not significantly improved.

Entities:  

Mesh:

Year:  2005        PMID: 16175621     DOI: 10.1002/hep.20871

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  50 in total

1.  Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension.

Authors:  Annalisa Berzigotti; Valentina Rossi; Carolina Tiani; Lucia Pierpaoli; Paola Zappoli; Anna Riili; Carla Serra; Pietro Andreone; Maria Cristina Morelli; Rita Golfieri; Cristina Rossi; Donatella Magalotti; Marco Zoli
Journal:  J Gastroenterol       Date:  2011-01-07       Impact factor: 7.527

Review 2.  Invasive and non-invasive diagnosis of cirrhosis and portal hypertension.

Authors:  Moon Young Kim; Woo Kyoung Jeong; Soon Koo Baik
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 3.  Natural history of cirrhosis.

Authors:  Sumeet K Asrani; Patrick S Kamath
Journal:  Curr Gastroenterol Rep       Date:  2013-02

4.  Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis.

Authors:  Maiko Namba; Akira Hiramatsu; Hiroshi Aikata; Kenichiro Kodama; Shinsuke Uchikawa; Kazuki Ohya; Kei Morio; Hatsue Fujino; Takashi Nakahara; Eisuke Murakami; Masami Yamauchi; Tomokazu Kawaoka; Masataka Tsuge; Michio Imamura; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2019-09-04       Impact factor: 7.527

Review 5.  Portal pressure monitoring-state-of-the-art and future perspective.

Authors:  Gang Xu; Fei Li; Yilei Mao
Journal:  Ann Transl Med       Date:  2019-10

Review 6.  Invasive and non-invasive assessment of portal hypertension.

Authors:  Jonathan Chung-Fai Leung; Thomson Chi-Wang Loong; James Pang; Jeremy Lok Wei; Vincent Wai-Sun Wong
Journal:  Hepatol Int       Date:  2017-03-30       Impact factor: 6.047

7.  Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Zobair M Younossi; Rohit Loomba; Mary E Rinella; Elisabetta Bugianesi; Giulio Marchesini; Brent A Neuschwander-Tetri; Lawrence Serfaty; Francesco Negro; Stephen H Caldwell; Vlad Ratziu; Kathleen E Corey; Scott L Friedman; Manal F Abdelmalek; Stephen A Harrison; Arun J Sanyal; Joel E Lavine; Philippe Mathurin; Michael R Charlton; Naga P Chalasani; Quentin M Anstee; Kris V Kowdley; Jacob George; Zachary D Goodman; Keith Lindor
Journal:  Hepatology       Date:  2018-07       Impact factor: 17.425

Review 8.  Invasive and non-invasive techniques for detecting portal hypertension and predicting variceal bleeding in cirrhosis: a review.

Authors:  Enrico Maria Zardi; Francesco Maria Di Matteo; Claudio Maurizio Pacella; Arun J Sanyal
Journal:  Ann Med       Date:  2013-12-16       Impact factor: 4.709

Review 9.  Noninvasive assessment of portal hypertension in cirrhosis: liver stiffness and beyond.

Authors:  Horia Stefanescu; Bogdan Procopet
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

10.  Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis.

Authors:  Amir A Qamar; Norman D Grace; Roberto J Groszmann; Guadalupe Garcia-Tsao; Jaime Bosch; Andrew K Burroughs; Cristina Ripoll; Rie Maurer; Ramon Planas; Angels Escorsell; Juan Carlos Garcia-Pagan; David Patch; Daniel S Matloff; Robert Makuch; Gabriel Rendon
Journal:  Clin Gastroenterol Hepatol       Date:  2009-03-10       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.